# Literature Review: APEX — An AI-Powered Pulmonary EXtended Aging Framework for Early Disease Detection and Characterization Using Chest Radiographs

## Introduction

Chest radiographs are among the most widely used imaging tests in clinical care, yet many AI systems built on them still focus primarily on disease classification. Recent work suggests that chest X-rays also contain information about biological aging, not just pathology labels. In particular, deep learning models have been shown to estimate a radiographic age from chest radiographs and associate that estimate with mortality and cardiopulmonary outcomes, indicating that imaging may reflect latent markers of tissue degeneration beyond chronological age [web:1][web:6][web:10].

This observation motivates APEX, a proof-of-concept framework that reframes pulmonary imaging as an aging problem rather than a pure classification task. Instead of predicting only whether a disease is present, APEX would learn a baseline model of normal pulmonary aging and measure how far an individual scan deviates from that expected trajectory. Such a framing may be useful for early detection, disease characterization, and interpretability, especially in conditions that progress gradually or subtly [web:1][web:10].

## Related Work

A key foundation for APEX is the finding that deep learning can estimate biological age from chest radiographs. Raghu et al. developed “CXR-Age” using more than 116,000 chest radiographs and showed that higher radiographic age predicted worse all-cause and cardiovascular mortality, even after adjustment for chronological age [web:1]. An external validation study in asymptomatic Asian individuals later found that CXR-Age also carried prognostic value for respiratory disease mortality and added predictive value beyond clinical factors [web:6]. Together, these studies support the idea that chest X-rays encode biologically meaningful information related to aging and disease burden [web:1][web:6].

Additional evidence comes from a 2023 multi-institutional study that developed a chest-radiography aging biomarker in healthy individuals and then tested whether the age difference between predicted and chronological age related to disease. That work found associations between “difference-age” and several chronic diseases, including chronic obstructive pulmonary disease and interstitial lung disease, suggesting that age deviation on chest radiographs may function as a general disease marker rather than a disease-specific classifier alone [web:10]. This is especially relevant to APEX because it supports the central hypothesis that disease can shift an estimated pulmonary aging trajectory in measurable ways [web:10].

## Dataset Context

For initial proof-of-concept work, the NIH ChestX-ray14 dataset is a reasonable starting point because it is large and publicly available. The dataset contains 112,120 frontal chest X-rays from 30,805 patients and includes labels for 14 thoracic findings plus “No Finding” [web:13][page:1]. The size of the dataset makes it useful for training deep models, but prior research also notes important limitations such as label noise, weakly mined labels, and cases where the label may reflect treated disease rather than active pathology [page:1]. These issues matter for APEX because the framework aims to model nuanced age-related signal, so data quality and careful split design are important for avoiding misleading conclusions [page:1].

ChestX-ray14 has also been widely used for multi-label thoracic disease classification, which makes it a familiar benchmark for comparing any new radiograph-based method. However, prior work has mostly treated it as a label-prediction problem, not as a source of continuous aging biomarkers. That creates an opportunity for APEX to explore a different representation of disease: one based on deviation from healthy aging rather than binary pathology presence [page:1][web:13].

## Interpretability Potential

One of the strongest reasons to explore APEX is interpretability. A continuous pulmonary age gap could be easier to reason about than a single disease probability, especially if the model can show where in the lungs the aging deviation occurs. Prior chest X-ray models have already used localization methods such as Grad-CAM to identify image regions most responsible for a prediction, and these maps have revealed that models can attend to clinically relevant structures but can also latch onto shortcuts such as chest drains in pneumothorax cases [page:1]. This suggests that regional explanation tools will be necessary if APEX is to produce trustworthy regional pulmonary aging maps rather than opaque scalar outputs [page:1].

The idea of regional aging is also consistent with broader trends in medical AI toward combining prediction with explanation. If APEX divides the lungs into anatomical regions and estimates regional age acceleration, it could help identify whether a disease produces diffuse aging, localized damage, or asymmetric patterns. That would make the system more informative than standard classification models, which usually collapse complex pathology into one label without describing how the lung structure has changed [web:1][web:10].

## Research Gap

Current literature supports the existence of radiographic aging signals, but it does not fully answer whether those signals can be decomposed into disease-specific aging signatures or localized regional patterns. Existing models mainly estimate a single age-like output or examine broad associations with mortality and disease [web:1][web:6][web:10]. APEX extends this line of work by proposing that different pulmonary diseases may distort the normal aging trajectory in distinct ways, producing measurable signatures that could improve characterization beyond diagnosis alone.

Another gap is that most age-estimation studies focus on prognosis rather than early disease detection. APEX would explore whether deviations from expected pulmonary aging appear before overt clinical labels, which could make the framework useful as an early warning biomarker. As a proof of concept, this is a plausible and novel direction, but it will require careful validation, robust external testing, and evaluation against label noise and confounding factors such as age, sex, and imaging view position [page:1][web:6].

## Conclusion

The existing literature provides a strong basis for APEX. Deep learning can estimate biologically meaningful age from chest radiographs, and age deviations have been linked to mortality and chronic disease burden [web:1][web:6][web:10]. At the same time, ChestX-ray14 offers a large but imperfect dataset that can support initial experimentation while also highlighting the need for careful validation [web:13][page:1].

As a proof-of-concept, APEX is compelling because it turns chest radiograph analysis from a categorical classification task into a continuous aging model. If successful, the framework could offer a more interpretable biomarker for pulmonary health and a new way to study how disease reshapes lung aging trajectories [web:1][web:10].
